Nicotinamide Riboside for Blood Pressure: New Study Results

SNIPPET: Nicotinamide riboside (NR), a NAD+ precursor supplement, may lower systolic blood pressure and improve vascular endothelial function in midlife and older adults with above-normal readings, according to data presented at the American Physiological Society. Magnesium and L-citrulline also show clinically meaningful BP reductions in recent controlled trials.

THE PROTOHUMAN PERSPECTIVE#

Look, hypertension is not a sexy biohacking topic. Nobody's posting their systolic readings on Instagram between cold plunge selfies. But here's the thing — elevated blood pressure is the single largest modifiable risk factor for cardiovascular death globally, responsible for roughly 7.6 million premature deaths each year. And the lifetime probability of developing it sits around 90%.

So when multiple 2025 studies converge on the same signal — that specific, well-characterized supplements can produce clinically detectable blood pressure reductions — that matters more for actual human longevity than most of what fills your feed. This isn't about replacing medication. It's about what happens in the gap between "your BP is creeping up" and "here's your prescription." That gap is where supplements like nicotinamide riboside, magnesium, and L-citrulline may earn a legitimate role. The data is fresh, the mechanisms are plausible, and for once, the effect sizes aren't trivial.

THE SCIENCE#

Nicotinamide Riboside: The NAD+ Angle on Vascular Health#

Nicotinamide riboside is a form of vitamin B3 that serves as a precursor to nicotinamide adenine dinucleotide (NAD+) — a coenzyme central to mitochondrial efficiency, DNA repair, and sirtuin activation. NAD+ levels decline with age, and this decline tracks uncomfortably well with vascular stiffening and endothelial dysfunction.

Research presented at the American Physiology Summit 2025 found that NR supplementation lowered systolic blood pressure and improved vascular endothelial function in midlife and older adults with above-normal systolic readings ^[1]. Wait, let me be more precise here — this was presented as a conference abstract, not a full peer-reviewed paper with complete methodology laid bare. That distinction matters. But the signal is consistent with earlier work from the University of Colorado showing NR could improve arterial compliance.

The proposed mechanism runs through NAD+ synthesis and its downstream effects on endothelial nitric oxide synthase (eNOS). More NAD+ means better sirtuin-1 activity, which upregulates eNOS, which means more nitric oxide, which means vasodilation. It's a clean chain. The question is whether oral NR at standard doses (500–1000 mg/day) raises vascular NAD+ enough to matter. The conference data suggests it might, at least in people who already have elevated systolic pressure.

I'm less convinced this will do anything meaningful for someone whose BP is already normal. The effect appears specific to the above-normal population — which, frankly, includes a disturbingly large percentage of adults over 45.

Magnesium: The Unsexy Workhorse#

Kisters et al. published a double-blinded, controlled, prospective study in the Journal of Hypertension examining magnesium supplementation in elderly individuals with metabolic syndrome ^[2]. The numbers are worth pausing on.

Systolic blood pressure dropped from 135.5 ± 5.4 to 128.2 ± 5.1 mmHg. Diastolic fell from 86.7 ± 3.3 to 79.2 ± 1.7 mmHg. That's a 7.3 mmHg systolic reduction and a 7.5 mmHg diastolic reduction over 12 weeks with 400–500 mg of organic magnesium (aspartate or citrate). The control group showed no significant change. Statistical significance at p < 0.01.

The mechanism here is calcium-magnesium antagonism. Magnesium modulates vascular smooth muscle tone by competing with calcium at the cellular level, reducing vasoconstriction. It also decreases inflammation and atherogenic vessel damage. This isn't new — magnesium's BP-lowering effect is well-documented — but what's useful about Kisters et al. is the specific context: metabolic syndrome in elderly patients, organic magnesium forms, and the additional finding on lipid profile improvement.

The study was small — 45 supplemented, 43 controls — so I'd want to see this replicated at larger scale. But it aligns with the broader meta-analytic literature, which consistently places magnesium's systolic BP reduction in the 3–7 mmHg range.

L-Citrulline: The Nitric Oxide Precursor Play#

Kang et al. (2025) examined L-citrulline supplementation in middle-aged and older adults with type 2 diabetes, looking at endothelial function, arterial stiffness, and blood glucose in both fasted and acute hyperglycemic states ^[3]. This is a more nuanced study than most citrulline trials because it specifically tests vascular function under metabolic stress — the hyperglycemic challenge.

L-citrulline converts to L-arginine in the kidneys, which then feeds nitric oxide production. The advantage over direct L-arginine supplementation is bioavailability — citrulline bypasses first-pass hepatic metabolism, delivering more substrate to the vascular endothelium. This matters for autophagy pathways and endothelial repair mechanisms that depend on adequate NO signaling.

The study, published in Nutrients, contributes to a growing body of evidence that citrulline may attenuate the vascular damage that accompanies acute blood sugar spikes — a critical concern for the diabetic population and anyone interested in HRV optimization and metabolic flexibility.

The Broader Nutraceutical Landscape#

A 2025 review by Verma et al. synthesized evidence across multiple nutraceuticals with clinically detectable BP-lowering effects ^[4]. The review found strong evidence supporting potassium, magnesium, L-arginine, vitamin C, cocoa flavonoids, beetroot juice, coenzyme Q10, controlled-release melatonin, and aged garlic extract. All dose-dependent. All generally safe.

But here's where it gets complicated. The melatonin data is increasingly messy. An observational study presented at the 2025 AHA Scientific Sessions flagged an 89% higher relative risk of heart failure in people using melatonin for over 12 months. Now — and I cannot stress this enough — that's relative risk without a clear absolute baseline, in a population that self-selects for chronic sleep problems (themselves an independent cardiovascular risk factor). Confounding by indication is written all over it. I wouldn't change my melatonin use based on that alone, but the controlled-release melatonin recommended in the Verma review deserves a more cautious framing than it once did.

COMPARISON TABLE#

THE PROTOCOL#

Based on current evidence, here is a practical approach if you're looking to support blood pressure through supplementation. This is not a replacement for medical advice — it's a framework informed by the latest data.

Step 1: Establish Your Baseline. Get an accurate resting blood pressure reading. Use an automated cuff at the same time each day for one week. Morning readings (before caffeine) are most informative. Record systolic and diastolic separately. If your systolic consistently reads above 120 mmHg, supplementation becomes more relevant.

Step 2: Start with Magnesium. This has the strongest and most replicated evidence base. Begin with 400 mg of magnesium citrate or magnesium aspartate daily, taken with dinner. The Kisters et al. study used 400–500 mg of organic magnesium for 12 weeks ^[2]. Avoid magnesium oxide — its bioavailability is poor. Expect measurable effects at 8–12 weeks.

Step 3: Add L-Citrulline for Endothelial Support. Take 3–6 g of L-citrulline daily, split into two doses (morning and pre-dinner). This supports nitric oxide synthesis through the arginine pathway. Kang et al. specifically examined effects in metabolic contexts ^[3], making this particularly relevant if you're managing blood glucose alongside blood pressure.

Step 4: Consider Nicotinamide Riboside. If your budget allows and you're interested in the NAD+ longevity angle, add 500 mg of NR daily, taken in the morning. The BP effects appear most relevant for adults with above-normal systolic pressure ^[1]. Monitor for 12 weeks before assessing impact.

Step 5: Track and Reassess. Continue daily BP monitoring. After 12 weeks, compare your average readings against your baseline. A systolic drop of 5–7 mmHg is clinically meaningful and consistent with the effect sizes in these studies. If you see no change, reassess dosing, timing, and whether the specific forms you're using match those in the research.

Step 6: Stack with Lifestyle Fundamentals. No supplement overcomes a bad foundation. The DASH dietary pattern, sodium restriction below 2,300 mg/day, 150+ minutes of aerobic exercise weekly, and adequate sleep remain the highest-impact interventions. Supplements operate in the margins — meaningful margins, but margins nonetheless.

What is nicotinamide riboside and how does it affect blood pressure?#

Nicotinamide riboside is a form of vitamin B3 that your body converts into NAD+, a coenzyme involved in cellular energy production and vascular health. Data presented at the American Physiology Summit 2025 suggests it may lower systolic blood pressure in midlife and older adults by improving endothelial function through the sirtuin-1/eNOS pathway ^[1]. Optimal dosing in humans for BP specifically is not yet firmly established — most trials use 500–1000 mg daily.

How much can magnesium supplementation reduce blood pressure?#

In the Kisters et al. double-blind trial, 400–500 mg of organic magnesium daily reduced systolic BP by approximately 7.3 mmHg and diastolic BP by 7.5 mmHg over 12 weeks in elderly patients with metabolic syndrome ^[2]. That's a clinically significant reduction — comparable to some first-line antihypertensive medications. The key is using bioavailable forms like citrate or aspartate, not oxide.

Why is L-citrulline preferred over L-arginine for blood pressure support?#

L-citrulline bypasses first-pass metabolism in the liver, meaning more of it reaches the kidneys where it converts to L-arginine and then to nitric oxide. Direct L-arginine supplementation loses a significant portion to hepatic breakdown before it can influence vascular tone. Kang et al. specifically demonstrated citrulline's effects on endothelial function in diabetic adults under metabolic stress conditions ^[3].

Who should consider these supplements for blood pressure?#

Adults with consistently above-normal systolic blood pressure (120–139 mmHg) who are not yet on prescription antihypertensives may benefit most. The NR and magnesium data specifically targeted midlife and older adults. If you're already on BP medication, talk to your physician before adding supplements — magnesium in particular can interact with certain drug classes, and stacking vasodilatory compounds requires monitoring.

When should you expect to see results from BP-lowering supplements?#

Most controlled trials show measurable effects at 8–12 weeks. The magnesium study by Kisters et al. assessed outcomes at 12 weeks ^[2]. Don't expect overnight changes — vascular remodeling and endothelial adaptation take time. If you see no change after 12 weeks of consistent use at studied doses, the intervention likely isn't working for your physiology.

VERDICT#

7.5/10. The convergence of 2025 data on NR, magnesium, and L-citrulline for blood pressure is genuinely encouraging — not because any single study is definitive, but because the mechanisms are distinct, the effect sizes are clinically meaningful, and the safety profiles are well-established. Magnesium is the strongest play here: cheap, well-studied, and effective. NR is the most interesting but needs more than a conference abstract to earn full confidence. L-citrulline fills a smart niche, especially for people managing metabolic health alongside BP. None of this replaces lifestyle fundamentals or prescription management when needed. But for the "my BP is trending up and I want to act before it becomes a diagnosis" crowd — and honestly, that's most of us past 40 — this stack has real merit.